





# Leap-In Transposase<sup>®</sup> Platform for Robust Cell Line Development

High Productivity  
Rapid Timelines  
Low Risk Development  
Robust Genetic Stability



# Transposition for robust cell line development


- Features:**
- Integration into transcriptionally active chromatin
  - The integrity of the transposon cassette remains intact
  - Genome integration via enzymatic cut-and-paste mechanism
  - Once integrated, the transposon remains integrated = stable



**Benefits:**

- High titer: Bulk pool up to 7g/L, clones >10g/L
- Rapid timelines: Transfection to RCB in ~10 weeks
- Predictable stability: > 90% of clones retain 100% of expression
- Robust tech-transfer: Predictable growth and titer across scales
- Low risk platform: 10 INDs in two years, broad market adoption

## From Transfection to RCB in ~10 weeks:



## Uniquely enabling bulk pools:

- Pool is predictive of clones: Titer and Product Quality
- High titer pools: Enable gram quantities of representative product
- Enable early process development - Upstream, Downstream, Analytics
- Utility in tox lot generation
- Pools have been used in two COVID-19 Phase I IND filings

### References:

Rajendran et.al., *Biotechnol. Bioeng.*, 2021, 118(6):2301-2311

10 IND clearances as of Nov 2021 (1 in China, 7 in U.S., 2 in Europe)

Protected by more than 10 issued patents

The Leap-In Transposase® platform is available for licensing or as a service provided by ATUM. miCHO™ and miHEK™ cell lines (GS) are available to purchase. Contact us for more information:

+1 650 853 8347


+1 877 DNA TOGO

info@atum.bio



+1 877 DNA TOGO  
+1 650 853 8347  
info@atum.bio

37950 Central Court  
Newark, CA 94560



research. create. break through.

